Val66Met polymorphism and serum brain‐derived neurotrophic factor in bipolar disorder: an open‐label trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: Brain‐derived neurotrophic factor (BDNF) is consistently associated with acute mood episodes in bipolar disorder, but there is a lack of longitudinal data to support this hypothesis. In this 16‐week open‐label clinical trial, we tested the predictive role of BDNF Val66Met polymorphism on serum BDNF levels and the relationship of serum BDNF and clinical response in people with bipolar disorder during an acute illness episode. Method: Sixty‐four people with bipolar disorder who were medication‐free at baseline and in an acute mood episode were recruited. They were matched with 64 healthy controls. Clinical evaluation, serum BDNF, and BDNF Val66Met polymorphism were determined at baseline, and change in serum BDNF was assessed in patients at weeks 2, 4, 8 and 16. Results: There were no differences between patients and controls in serum BDNF or in frequencies of the BDNF Val66Met polymorphism genotype at baseline. The multivariable model showed that Met carriers had a significantly different change in BDNF levels compared with Val homozygotes. Not achieving a complete remission was also associated with lower prospectively assessed BDNF levels. Conclusion: This study provides the first longitudinal evidence that both the BDNF Val66Met polymorphism and remission status predict change in circulating BDNF levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“Neuronal survival and apoptosis are regulated by key molecules, among them the class of neurotrophins (3).”
BackgroundTransport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationInteraction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“The high affinity of quetiapine for the serotonin-2A receptor and a subsequent increase in BDNF levels could also be argued as an explanation for the higher BDNF levels in this group (35, 39, 40).”
BackgroundVerhagen, M., van der Meij, A., van Deurzen, P. A. M., Janzing, J. G. E., Arias-Vásquez, A., Buitelaar, J. K., & Franke, B. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.109 · Cited by 470
Molendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.98 · Cited by 437 · cited 2×
“(35) compared the close link between clinical response and serum BDNF levels in patients with major depressive disorder.”
BackgroundWILLETT, J. B., SINGER, J. D., & MARTIN, N. C. (1998) · Development and Psychopathology · doi:10.1017/s0954579498001667 · Cited by 423
Fernandes, B. S., Gama, C. S., Maria Ceresér, K., Yatham, L. N., Fries, G. R., Colpo, G., de Lucena, D., Kunz, M., Gomes, F. A., & Kapczinski, F. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.002 · Cited by 389
Self-citationDeterminants of serum brain-derived neurotrophic factor.
Bus, B. A. A., Molendijk, M. L., Penninx, B. J. W. H., Buitelaar, J. K., Kenis, G., Prickaerts, J., Elzinga, B. M., & Voshaar, R. C. O. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.07.013 · Cited by 279
Cited by
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationFernandes, B. S., Molendijk, M. L., Köhler, C. A., Soares, J. C., Leite, C. M. G. S., Machado-Vieira, R., Ribeiro, T. L., Silva, J. C., Sales, P. M. G., Quevedo, J., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0529-7 · Cited by 291
“Six studies in mania provided data regarding drug-free subjects [8, 50, 57, 61, 70, 87] and three regarding drug-free persons with depression [50, 68, 81].”
BackgroundResultInfluentialSelf-citationPolacchini, A., Metelli, G., Francavilla, R., Baj, G., Florean, M., Mascaretti, L. G., & Tongiorgi, E. (2015) · Scientific Reports · doi:10.1038/srep17989 · Cited by 263
Munkholm, K., Vinberg, M., & Kessing, L. V. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.54 · Cited by 157
Metadata
- Authors
- Grande, I., Magalhães, P. V. S., Chendo, I., Stertz, L., Fries, G. R., Cereser, K. M., Cunha, Â. B. M., Gói, P., Kunz, M., Udina, M., Martín‐Santos, R., Frey, B. N., Vieta, E., & Kapczinski, F.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2013-08-20
- Volume
- 129
- Issue
- 5
- Pages
- 393-400
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2019789178
- Cited by
- 26
- References
- 12
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Val66Met polymorphism and serum brain‐derived neurotrophic factor in bipolar disorder: an open‐label trial. https://app.cochat.ai/papers/10.1111/acps.12192
- The paper
- Grande, I., Magalhães, P. V. S., Chendo, I., Stertz, L., Fries, G. R., Cereser, K. M., Cunha, Â. B. M., Gói, P., Kunz, M., Udina, M., Martín‐Santos, R., Frey, B. N., Vieta, E., & Kapczinski, F. (2014). Val66Met polymorphism and serum brain‐derived neurotrophic factor in bipolar disorder: an open‐label trial. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.